Clinical Report: GA Gene Therapy Interest Increases
Overview
PulseSight Therapeutics has completed a phase 1 trial of PST-611, a non-viral gene therapy for geographic atrophy (GA). Initial findings suggest potential safety and tolerability, with results expected to be presented at ARVO 2026.
Background
Geographic atrophy (GA) is a significant cause of vision loss in patients with dry age-related macular degeneration (AMD), and current treatment options are limited. The development of gene therapies like PST-611 represents a promising avenue for addressing this unmet clinical need. Understanding the safety and efficacy of such therapies is crucial as they may offer new hope for preserving visual function in affected patients.
Data Highlights
No numerical data available from the trial at this stage.
Key Findings
- PST-611 is a non-viral gene therapy candidate targeting geographic atrophy.
- The phase 1 trial evaluated safety and tolerability in six patients with dry AMD/GA across two dose cohorts.
- Results will be presented by Professor Francine Behar-Cohen at ARVO 2026.
- The therapy aims to express transferrin, which is involved in iron regulation, potentially mitigating oxidative stress in retinal cells.
- PulseSight's electro-transfection method delivers DNA plasmids to the ciliary muscle, acting as a biofactory for therapeutic protein production.
- Gene-based approaches to retinal disease are gaining increased interest as potential alternatives to current treatments.
Clinical Implications
The findings from the PST-611 trial may inform future clinical practices regarding gene therapy for GA. As the field evolves, clinicians should stay updated on emerging therapies and consider their potential benefits in managing dry AMD, while ongoing research continues to shape treatment options.
Conclusion
The completion of the phase 1 trial for PST-611 marks a significant step in the exploration of gene therapy for geographic atrophy. Continued research and forthcoming results, particularly the upcoming ARVO presentation, will be critical in determining the viability of this treatment approach.
References
- Katherine E. Talcott, MD, FASRS, Ophthalmology Management, 2024 -- Gene Therapy for Retinal Disease Recommendations
- M. Ali Khan, MD, Allen C. Ho, MD, Retinal Physician, 2020 -- The Eye as a Biofactory
- Thomas A. Ciulla, MD, MBA, Michael Gemayel, MD, Ophthalmic Professional, 2020 -- Introduction to gene therapy
- Retinal Physician, 2026 -- Gene Therapy for GA Receives FDA Fast Track Designation
- AAO 2025: Age-Related Macular Degeneration Guidelines - Medthority
- Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy, 2026
- AAO 2025: Age-Related Macular Degeneration Guidelines - Medthority
- Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy - Paul Hahn, David Eichenbaum, Dilsher S. Dhoot, Charles C. Wykoff, Michael A. Klufas, Michele Intorcia, Daniel Jones, Sujata P. Sarda, Priyanka Bobbili, Rose Chang, Maryaline Catillon, Chunyi Xu, Kirthana Sarathy, Mei Sheng Duh, Caroline R. Baumal, Varun Chaudhary, 2026
- https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-07-16-05-00-00-3116124-en.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
